Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL:a phase 2, open-label trial

Autor: Wolfgang Willenbacher, Brian Fox, Peter de Nully Brown, Judit Jørgensen, Neus Domper Rubio, Marie-Laure Casadebaig, Richard Greil, Hele Everaus, Ulrich Jäger, Lorenz Trümper, David Cunningham, Oliver Manzke, Thomas Stauffer Larsen, Krish Patel, Justine Dell’Aringa, Nurgul Kilavuz, Grzegorz S. Nowakowski, Nagesh Kalakonda, Robert Manges, Javier Munoz

Publikováno v: Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell’Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d8c12cf157023fa610230261b321fc
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009

INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Autor: Francis Seguy, Christophe Bonnet, Oliver Manzke, Di Li, Björn E. Wahlin, Shankara Paneesha, Marek Trneny, K. Hübel, Stefano Luminari, Laurie H. Sehn, Ajay K. Gopal, C. W. Scholz, Antonio Salar

Publikováno v: Hematological Oncology. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46d95ea39cd5561fe3cfe55b406aa259
https://doi.org/10.1002/hon.175_2880

Poster: IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Autor: Laurie H. Sehn, Christian W. Scholz, Stefano Luminari, Antonio Salar, Björn E. Wahlin, Ajay K. Gopal, Christophe Bonnet, Marek Trneny, Shankara Paneesha, Oliver Manzke, Francis Seguy, Di Li, Kai Hübel

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S246

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1696ffb111d2c965f3522a4af69f66db
https://doi.org/10.1016/s2152-2650(21)01550-0

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL

Autor: Robert Manges, Javier Munoz, Neus Domper, Jeanna Knoble, Ulrich Jäger, Grzegorz S. Nowakowski, Nagesh Kalakonda, Lorenz Trümper, Judit Joergensen, Richard Greil, Wolfgang Willenbacher, Thomas Stauffer Larsen, Oliver Manzke, Krish Patel, David Cunningham, Hele Everaus, Marie-Laure Casadebaig, Peter de Nully Brown, Corinne Haioun

Publikováno v: Journal of Clinical Oncology. 37:7520-7520

7520 Background: We report results of a phase 2, open-label study of durvalumab (durva) in combination with R-CHOP or R2-CHOP (R-CHOP + lenalidomide) in previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Methods: Subjects (≥18 y

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36eb90a79d29b8083eb095304fa50474
https://doi.org/10.1200/jco.2019.37.15_suppl.7520

Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L

Autor: Claudia Wickenhauser, Marc Beyer, Joachim L. Schultze, Michael von Bergwelt-Baildon, F. Fiore, Oliver Manzke, Alexey Popov, Stefan E. Baldus, Uta Drebber

Publikováno v: Leukemia & Lymphoma. 47:613-622

Despite the lack of tumor control, infiltration of immune cells has been demonstrated for several malignancies including non-Hodgkin's lymphoma. Since dendritic cells play a pivotal role in the initiation and control of the immune response, the frequ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9094a629e7d97ddf434f09c0a5eb266f
https://doi.org/10.1080/10428190500360971